CD19 and non-Hodgkin lymphoma: Despite the promising early results of blinatumomab supporting the TCE approach for NHL, the emergence of anti-CD19‐directed CAR-T cells, with four different products approved by the FDA, may have discouraged subsequent BsAb development.